ReviewBrain pathology (Zurich, Switzerland)2020
Epigenome-wide association studies in Alzheimer's disease; achievements and challenges.
Review in Brain pathology (Zurich, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Entorhinal cortex epigenome-wide association study highlights four novel loci showing differential methylation in Alzheimer's disease.Alzheimer's research & therapy · 2023Pooled it
- The complement cascade in Alzheimer's disease: modern implications of an ancient immune protagonist.Molecular neurodegeneration · 2025Review
- Blood-based multivariate methylation risk score for cognitive impairment and dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Targeted Methylation Profiling of Single Laser-Capture Microdissected Post-Mortem Brain Cells by Adapted Limiting Dilution Bisulfite Pyrosequencing (LDBSP).International journal of molecular sciences · 2022Article
- Advances in Genetics and Epigenetic Alterations in Alzheimer's Disease: A Notion for Therapeutic Treatment.Genes · 2021Review
- Applying gene-editing technology to elucidate the functional consequence of genetic and epigenetic variation in Alzheimer's disease.Brain pathology (Zurich, Switzerland) · 2020Article
- The molecular etiology of Alzheimer's disease.Brain pathology (Zurich, Switzerland) · 2020Article
- Considerations for integrative multi-omic approaches to explore Alzheimer's disease mechanisms.Brain pathology (Zurich, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
Abstract
Alzheimer's disease (AD) represents a devastating progressive neurodegenerative disease with a complex pathophysiology, affecting millions of people worldwide. Recent epigenome-wide association studies suggest a key role for epigenetic mechanisms in its development and course. Despite the fact that current evidence on the role of epigenetic dysregulation in aging and AD is convincing, the pioneering field of neuroepigenetics is still facing many challenges that need to be addressed to fundamentally increase our understanding about the underlying mechanisms of this neurodegenerative disorder. This perspective paper describes the current state of play for epigenetic research into AD and discusses how new methodological advances in the field of epigenetics and related data science disciplines could further spur the development of novel therapeutic agents and biomarker assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.